CSS
HZNP

Cubist Systematic Strategies’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cubist Systematic Strategies’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,181
Closed -$4.12M – 4836
2022
Q4 		$4.12M Sell
36,181
-61,529
-63% -$5.11M 0.02% 1198
2022
Q3 		$6.05M Sell
97,710
-8,339
-8% -$583K 0.03% 895
2022
Q2 		$8.46M Buy
106,049
+16,513
+18% +$1.56M 0.05% 554
2022
Q1 		$9.42M Buy
89,536
+9,198
+11% +$896K 0.08% 329
2021
Q4 		$8.66M Buy
80,338
+11,262
+16% +$1.23M 0.08% 315
2021
Q3 		$7.57M Buy
69,076
+56,179
+436% +$5.83M 0.1% 281
2021
Q2 		$1.21M Buy
12,897
+184
+1% +$16.9K 0.01% 1430
2021
Q1 		$1.17M Buy
+12,713
New +$1.07M 0.02% 1429
2020
Q4 		– Sell
-173,262
Closed -$13.5M – 2817
2020
Q3 		$13.5M Buy
173,262
+138,305
+396% +$9.52M 0.2% 70
2020
Q2 		$1.94M Sell
34,957
-3,800
-10% -$163K 0.03% 810
2020
Q1 		$1.15M Buy
38,757
+26,957
+228% +$912K 0.03% 748
2019
Q4 		$427K Sell
11,800
-79,280
-87% -$2.43M 0.01% 1640
2019
Q3 		$2.48M Sell
91,080
-127,049
-58% -$3.29M 0.05% 536
2019
Q2 		$5.25M Buy
218,129
+8,999
+4% +$228K 0.1% 287
2019
Q1 		$5.53M Buy
+209,130
New +$4.96M 0.18% 107
2018
Q4 		– Sell
-25,222
Closed -$494K – 2416
2018
Q3 		$494K Buy
25,222
+11,952
+90% +$227K 0.03% 835
2018
Q2 		$220K Sell
13,270
-61,464
-82% -$937K 0.01% 1289
2018
Q1 		$1.06M Sell
74,734
-8,519
-10% -$126K 0.06% 405
2017
Q4 		$1.22M Buy
83,253
+33,760
+68% +$474K 0.06% 391
2017
Q3 		$628K Buy
49,493
+44,433
+878% +$565K 0.04% 678
2017
Q2 		$60K Sell
5,060
-11,713
-70% -$146K ﹤0.01% 1522
2017
Q1 		$248K Sell
16,773
-862
-5% -$14K 0.02% 1037
2016
Q4 		$285K Sell
17,635
-19,240
-52% -$349K 0.02% 991
2016
Q3 		$669K Sell
36,875
-39,545
-52% -$773K 0.04% 587
2016
Q2 		$1.26M Buy
76,420
+60,920
+393% +$986K 0.07% 357
2016
Q1 		$257K Sell
15,500
-356
-2% -$6.23K 0.01% 1074
2015
Q4 		$344K Sell
15,856
-110,450
-87% -$2.15M 0.02% 1039
2015
Q3 		$2.5M Buy
126,306
+46,306
+58% +$1.46M 0.13% 177
2015
Q2 		$2.78M Buy
80,000
+70,840
+773% +$2.16M 0.14% 182
2015
Q1 		$238K Buy
9,160
+1,446
+19% +$26.5K 0.01% 1414
2014
Q4 		$99K Buy
7,714
+3,814
+98% +$47.7K 0.01% 1698
2014
Q3 		$48K Buy
+3,900
New +$45.3K ﹤0.01% 1639

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's HZNP Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 36,181 shares — an estimated $4.12M sold.

Cubist Systematic Strategies first reported a position in HZNP in Q3 2014 and held it in 32 quarters. The position peaked at $13.5M in Q3 2020. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 36,181 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $4.12M.
  • Cubist Systematic Strategies first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 32 quarters.
  • Cubist Systematic Strategies's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $13.5M in Q3 2020.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.